Critical Care Department and Cerebral Resuscitation Research Group, Ghent University, De Pintelaan 185, 9000 Ghent, Belgium.
Curr Neuropharmacol. 2014 Sep;12(5):399-412. doi: 10.2174/1570159X12666140424233036.
Abrupt deprivation of substrates to neuronal tissue triggers a number of pathological events (the "ischemic cascade") that lead to cell death. As this is a process of delayed neuronal cell death and not an instantaneous event, several pharmacological and non-pharmacological strategies have been developed to attenuate or block this cascade. The most promising neuroprotectant so far is therapeutic hypothermia and its beneficial effects have inspired researchers to further improve its protective benefit by combining it with other neuroprotective agents. This review provides an overview of all neuroprotective strategies that have been combined with therapeutic hypothermia in rodent models of focal cerebral ischemia. A distinction is made between drugs interrupting only one event of the ischemic cascade from those mitigating different pathways and having multimodal effects. Also the combination of therapeutic hypothermia with hemicraniectomy, gene therapy and protein therapy is briefly discussed. Furthermore, those combinations that have been studied in a clinical setting are also reviewed.
突然剥夺神经元组织的底物会引发一系列病理事件(“缺血级联反应”),导致细胞死亡。由于这是一个延迟性神经元细胞死亡的过程,而不是一个瞬间事件,因此已经开发了几种药理学和非药理学策略来减轻或阻断这种级联反应。到目前为止,最有前途的神经保护剂是治疗性低温,其有益作用激发了研究人员通过将其与其他神经保护剂结合来进一步提高其保护作用。这篇综述概述了所有已在局灶性脑缺血的啮齿动物模型中与治疗性低温相结合的神经保护策略。从仅中断缺血级联反应的一种事件的药物到减轻不同途径和具有多模式作用的药物进行了区分。此外,还简要讨论了治疗性低温与去骨瓣减压术、基因治疗和蛋白质治疗的联合应用。此外,还综述了那些已在临床环境中研究过的组合。